Back to top
more

Eli Lilly (LLY)

(Delayed Data from NYSE)

$1,160.00 USD

1,160.00
2,520,342

+3.27 (0.28%)

Updated Sep 1, 2026 04:04 PM ET

After-Market: $1,159.50 -0.50 (-0.04%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.80%
2Buy18.13%
3Hold10.19%
4Sell5.73%
5Strong Sell3.17%
S&P50011.53%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value A Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 39% (97 out of 248)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Kinjel Shah headshot

Beyond GLP-1: Eli Lilly's Expanding Drug Portfolio Lifts Sales

by Kinjel Shah

LLY???s newest approvals and pipeline deals add fresh momentum to revenue growth as the company expands beyond its GLP-1 blockbusters.

Kinjel Shah headshot

AbbVie Stock Rebounds After Q3 Dip: Time to Buy, Hold or Sell?

by Kinjel Shah

ABBV rebounds after its Q3 dip as strong immunology and neuroscience growth offset Humira erosion and aesthetics weakness.

Zacks Equity Research

The Zacks Analyst Blog Highlights Microsoft, Amazon.com and Eli Lilly

by Zacks Equity Research

Microsoft posts strong cloud-fueled Q1 results as Azure surges and AI momentum builds, even as capacity limits pose near-term revenue constraints.

Mark Vickery headshot

Top Research Reports for Microsoft, Amazon.com & Eli Lilly

by Mark Vickery

Microsoft shines in Zacks' top picks as strong cloud and AI momentum drive standout quarterly results and reinforce long-term growth potential.

Zacks Equity Research

RHHBY Reports Positive Phase III Data on Breast Cancer Drug

by Zacks Equity Research

Roche reports strong phase III lidERA results as giredestrant delivers meaningful iDFS gains over standard endocrine therapy.

Kinjel Shah headshot

Pfizer Trading Above 50-Day SMA: Is it a Good Time to Buy the Stock?

by Kinjel Shah

PFE trades above its 50-day SMA on recent gains from the Metsera acquisition and a drug pricing agreement with the U.S. administration.

Zacks Equity Research

The Zacks Analyst Blog Highlights Eli Lilly, Johnson & Johnson and Adverum

by Zacks Equity Research

Lilly shines for growth seekers while J&J offers steady, lower-risk stability as both pharma giants advance pipelines and post rising estimates.

Ahan Chakraborty headshot

NVO Down 10% in 3 Months: Is This an Indication to Sell the Stock?

by Ahan Chakraborty

Novo Nordisk stock falls 10% in three months as guidance cuts, GLP-1 rivalry and looming U.S. price resets cloud growth and elevate execution risks.

Zacks Equity Research

Here is What to Know Beyond Why Eli Lilly and Company (LLY) is a Trending Stock

by Zacks Equity Research

Recently, Zacks.com users have been paying close attention to Lilly (LLY). This makes it worthwhile to examine what the stock has in store.

Kinjel Shah headshot

Growth or Stability? A 2025 Investment Face-Off Between LLY and JNJ

by Kinjel Shah

Eli Lilly's surging GLP-1 momentum and Johnson & Johnson's diversified strength set up a compelling 2025 showdown for investors weighing growth vs. stability.